Curaleaf lifted its hostile offer for Aurora Cannabis to $5 per share, saying its proposal relied on public data and calling for a fair process for shareholders.

Curaleaf launched a hostile takeover offer for Aurora, moving the proposal directly to investors. Here’s what that could mean for product supply, delivery compliance, and DMV consumers.

Aurora told investors to reject Curaleaf’s unsolicited $272M hostile bid and formed a special committee. Here’s what it could mean for delivery models, investors, and the DMV market.

Curaleaf urges Aurora investors to accept a $4-per-share hostile offer it says carries a 45% VWAP premium; Aurora calls the bid inadequate and risky. Here’s the business impact and DMV angle.

Curaleaf’s hostile push for Aurora isn’t just about a headline premium. It spotlights cash, debt, and market position — and how consolidation could reshape delivery.

Medical cannabis producer Aurora hires biopharmaceutical veteran Faris El Refaie to spearhead international growth and commercial operations.

Aurora says it is debt‑free with CA$149M cash and urges shareholders to reject Curaleaf’s hostile $4‑per‑share offer, warning the deal discounts assets and shifts risk.

Aurora told shareholders not to tender to Curaleaf’s hostile bid and signaled it’s weighing alternatives, sharpening focus on valuation, upside sharing, and voting control.